|
|
T S Tsao, A E Stenbit, J Li, K L Houseknecht, J R Zierath, E B Katz, M J Charron
J Clin Invest. 1997;
100(3):671
doi:10.1172/JCI119579
Abstract |
Full text
| PDF

W
e have taken the approach of introducing the muscle-specific myosin light chain (MLC)-GLUT4 transgene into the GLUT4-null background to assess the relative role of muscle and adipose tissue GLUT4 in the etiology of the GLUT4-null phenotype. The resulting MLC-GLUT4-null mice express GLUT4 predominantly in the fast-twitch extensor digitorum longus (EDL) muscle. GLUT4 is nearly absent in female white adipose tissue (WAT) and slow-twitch soleus muscle of both sexes of MLC-GLUT4-null mice. GLUT4 content in male MLC-GLUT4-null WAT is 20% of that in control mice. In transgenically complemented EDL muscle, 2-deoxyglucose (2-DOG) uptake was restored to normal (male) or above normal (female) levels. In contrast, 2-DOG uptake in slow-twitch soleus muscle of MLC-GLUT4-null mice was not normalized. With the normalization of glucose uptake in fast-twitch skeletal muscle, whole body insulin action was restored in MLC-GLUT4-null mice, as shown by the results of the insulin tolerance test. These results demonstrate that skeletal muscle GLUT4 is a major regulator of skeletal muscle and whole body glucose metabolism. Despite normal skeletal muscle glucose uptake and insulin action, the MLC-GLUT4-null mice exhibited decreased adipose tissue deposits, adipocyte size, and fed plasma FFA levels that are characteristic of GLUT4-null mice. Together these results indicate that the defects in skeletal muscle and whole body glucose metabolism and adipose tissue in GLUT4-null mice arise independently.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(19)
| Title and authors |
Publication |
Year |
Chromium Improves Glucose Uptake and Metabolism Through Upregulating the mRNA Levels of IR, GLUT4, GS, and UCP3 in Skeletal Muscle Cells
Wei Qiao, Zhongli Peng, Zhisheng Wang, Jing Wei, Anguo Zhou
|
Biol Trace Elem Res
|
2009 |
GLUT4
Jacqueline Stöckli, David James
|
AfCS-Nature Molecule Pages
|
2009 |
Recombinant Human Growth Hormone
Stefano Benedini, Ileana Terruzzi, Adriano Lazzarin, Livio Luzi
|
BioDrugs
|
2008 |
Novel food ingredients for weight control
A. Palou, M. L. Bonet
|
Novel food ingredients for weight control
|
2007 |
Hypotension, lipodystrophy, and insulin resistance in generalized PPARγ-deficient mice rescued from embryonic lethality
Sheng Zhong Duan, Christine Y. Ivashchenko, Steven E. Whitesall, Louis G. D’Alecy, Damon C. Duquaine, Frank C. Brosius, Frank J. Gonzalez, Charles Vinson, Melissa A. Pierre, David S. Milstone, Richard M. Mortensen
|
J. Clin. Invest.
|
2007 |
Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1
L. Al-Khalili, M. Forsgren, K. Kannisto, J. R. Zierath, F. Lönnqvist, A. Krook
|
Diabetologia
|
2005 |
USE OF GLUT-4 NULL MICE TO STUDY SKELETAL MUSCLE GLUCOSE UPTAKE
Maureen J Charron, Naira Gorovits, J Skye Laidlaw, Mollie Ranalletta, Ellen B Katz
|
Clinical and Experimental Pharmacology and Physiology
|
2005 |
Chromosomal Localization and Mutation Detection of the Porcine APM1 Gene Encoding Adiponectin
|
Journal of Animal Science and Technology
|
2004 |
What we know about facilitative glucose transporters: Lessons from cultured cells, animal models, and human studies
Naira Gorovits, Maureen J. Charron
|
Biochem. Mol. Biol. Educ.
|
2003 |
Gene and Cell Therapies for Diabetes Mellitus
Nick Giannoukakis, Paul D. Robbins
|
BioDrugs
|
2002 |
|